Navigation Links
NeoVista, Inc. Announces Initial VIDION Shipments
Date:10/30/2009

Hospital in Pisa, Italy is First in World to Receive Revolutionary Epimacular Brachytherapy System

Fremont, CA and Pisa, Italy (PRWEB) October 30, 2009 -- NeoVista, Inc. announced today that the first VIDION® ANV Therapy System for epimacular brachytherapy has been sold and shipped. Unlike anti-VEGF therapy, which requires frequent costly eye injections for an indefinite period of time, NeoVista's novel therapy delivers a one-time dose of radiation via a very commonly used surgical procedure called 'vitrectomy'. NeoVista's epimacular brachytherapy has been shown to be safe and effective in preliminary clinical trials and may offer a cost effective solution to the current treatment burden posed by continuous injections of anti-VEGF therapy.

Dr. Stanislao Rizzo, a world-renowned retinal surgeon from S. Chiara Hospital, Azienda Ospedaliero Universitaria Pisana,Pisa, Italy, said, "We are very excited to be the first hospital to receive this innovative one time treatment procedure, which can help to treat a devastating disease that otherwise requires chronic treatment for an indefinite period of time. NeoVista's targeted epimacular brachytherapy treatment may provide us the ability to improve vision by offering a distinct mechanism of action to conventional anti-VEGF therapy that affects multiple disease pathways, and may dramatically change the patients' quality of life by eliminating frequent eye injections. This promising treatment could very well be a cost-effective alternative to treating neovascular AMD," continued Dr. Rizzo. "Monthly injections can become quite expensive for our health care system, whereas a single procedure will potentially allow our specialists to treat more patients and bring down the costs associated with ongoing treatments while still providing satisfactory outcomes."

Unlike previous radiation therapies for wet AMD, NeoVista's innovative device delivers the peak dose of strontium-90 beta ionizing radiation directly to the lesion minimizing exposure to the surrounding tissue. The minimally invasive procedure utilizes a device similar in size to a needle, to deliver a highly targeted dose of beta radiation directly to the area of the retina affected by wet AMD. Importantly for patients, the systemic radiation exposure is minimal, as the effective dose to the entire body from NeoVista's epimacular brachytherapy device is comparable to a routine chest x-ray.

"This is a pivotal milestone for NeoVista, as the impact of VIDION's launch will greatly benefit patients, physicians, caregivers, and health care systems world-wide," stated John N. Hendrick, President and CEO of NeoVista. "We are looking forward to bringing the VIDION ANV Therapy System to millions of European patients with wet AMD who are seeking a more cost-efficient option that we expect will be as effective, if not better, than the current standard of care."

About Wet AMD
Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, where they leak blood and fluid, causing scar tissue to form and vision to become impaired. With wet AMD, vision loss may occur faster and be more noticeable than with dry AMD. The longer the abnormal vessels leak or grow, the more detail vision will be lost. The earlier wet AMD is diagnosed, the better the patients' chance of preserving some or much of their central vision.

About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Fremont, California. NeoVista's epimacular brachytherapy procedure is currently being studied in a definitive Phase III clinical study to support eventual filing for regulatory approval to market the product in the United States. For more information about the company or this novel wet AMD therapy, please visit the company's Web site at http://www.neovistainc.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3135124.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among ... all types and genders. And the need for advanced services is growing. , ... top-rated cancer care program, in collaboration with their non-profit partners in their fight against ...
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... (PII) celebrates the pharmaceutical companies that are most successful at ... ... question: if you gave the same molecule to two different ... it? Based on systematic, objective analysis of each ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
(Date:2/27/2017)... 27, 2017 The Dutch secure ... for use at the security level RESTRICTED. The solution thus ... organization for the communication of classified information. ... Sectra and Samsung have ... eavesdrop-secure smartphone solution. Sectra Tiger/R is developed by Sectra under ...
Breaking Medicine Technology: